Generic Estrace is used for treating conditions due to menopause (eg, hot flashes; vaginal itching, burning, or dryness), treating vulval or vaginal atrophy, and preventing osteoporosis (brittle bones). It is also used for estrogen replacement therapy after failure of the ovaries and to relieve the symptoms of breast cancer. More info »
Generic Evista is used for treating and preventing osteoporosis (bone thinning) in women who are past menopause. It is also used to reduce the risk of invasive breast cancer in certain women who are past menopause. More info »
Generic Premarin is used for treating certain symptoms of menopause (eg, hot flashes, vaginal dryness or itching). It is used to prevent osteoporosis (weak bones) after menopause in certain patients. It is also used in certain patients to treat low estrogen levels, prostate cancer or breast cancer. More info »
Hi.
just want to say thanks for your promt and efficient service.. The tablets arrived well within the timeframe given.. Have passed on your
address, dont know wheather its been used or not..
Best regards... and happy St Patricks from the Irish in France..
- Kieran
FDA panel votes against wider use of Amgen drug - Fox News
USA TODAYFDA panel votes against wider use of Amgen drugFox NewsThat rate is far higher than has been seen with widely used osteoporosis drugs.
Osteoporosis Medication Linked to Unusual Thigh Fractures - WebMD
Osteoporosis Medication Linked to Unusual Thigh FracturesWebMDOverall, most people with osteoporosis, a loss of bone density over time, will suffer fewer broken bones if they take bisphosphonates, a category of drugs including Actonel, Atelvia, Boniva, and Fosamax that are used to treat the disease.
Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical ... - MarketWatch (press release)
Halting Bone-Building Osteoporosis Drug Use Cuts Risk for Additional Atypical .
Heart Failure, Osteoporosis Go 'Hand-in-Hand': Researchers - Health.com
MedPage TodayHeart Failure, Osteoporosis Go 'Hand-in-Hand': ResearchersHealth.
Osteoporosis drug developer Radius Health braves chilly IPO market - FierceBiotech
Osteoporosis drug developer Radius Health braves chilly IPO marketFierceBiotechAfter burning through more than $122 million, the late-stage osteoporosis drug developer Radius Health is filing to go public in the hope of raising up to $86 million.
